



## Personalized Approaches for the Prevention and Treatment of Breast Cancer

Guest Editor:

**Prof. Dr. Hermann Nabi**

Department of Social and Preventive Medicine, Faculty of Medicine, Laval University, Québec, QC G1V 0A6, Canada

Deadline for manuscript submissions:  
**closed (20 March 2022)**

### Message from the Guest Editor

Dear Colleagues,

Thanks to advances in our understanding of cancer biology, breast cancer is now recognized as more than one disease, which has been instrumental in the development of tailored therapeutic strategies in patients with breast cancer, including endocrine and targeted therapies and maybe soon immunotherapy. However, primary or acquired resistances to these therapies are a major clinical obstacle, with a significant proportion of breast cancer patients experiencing disease progression and death while taking these medications. Progress in genomics and the advent of new sequencing technologies have also paved the way for personalized approaches to early detection or prevention of breast cancer, even though their implementation at a population level faces considerable challenges. This Special Issue of the *Journal of Personalized Medicine* welcomes manuscripts focusing on personalized approaches relevant to breast cancer detection, diagnosis, treatment, and survivorship. The types of studies or perspectives expected include clinical, population-based, and interventional studies as well as ethical, social, legal, and economic analyses.

Prof. Dr. Hermann Nabi  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer  
Institute, Winston-Salem, NC  
27103, USA  
2. Division of Hematologic  
Malignancies and Cellular  
Therapy, Duke University,  
Durham, NC 27710, USA

## Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM; ISSN 2075-4426)* is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

**Journal Rank:** JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

---

*Journal of Personalized Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/jpm](http://mdpi.com/journal/jpm)  
[jpm@mdpi.com](mailto:jpm@mdpi.com)  
[X@JPM\\_MDPI](https://twitter.com/JPM_MDPI)